Accordingly, in addition to the unadjusted univariate analyses and an age- and sex-adjusted model (Model 1), TRPG decrease for the risk of primary and secondary endpoints were assessed by using Model 2 which included age, sex, diabetes, AF/AFL, history of PMI, history of stroke, serum hemoglobin, serum albumin, eGFR, and logarithm (log-) NT-proBNP. This evidence concerns the gene NPPB and atrial fibrillation.